ORPHA:228012
Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome
Also known as: Progressive neurosensory deafness-hypertrophic cardiomyopathy syndrome · Progressive neurosensory hearing loss-hypertrophic cardiomyopathy syndrome · Progressive sensorineural deafness-hypertrophic cardiomyopathy syndrome
Publications
1
8th percentile
Trials
0
Interventional, condition-specific
Researchers
2
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder characterized by , late onset, sensorineural hearing loss, QT interval prolongation, and mild cardiac hypertrophy.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016424
- UMLS:C4304831
Additional Mondo synonyms (3)
progressive neurosensory deafness-hypertrophic cardiomyopathy syndrome · progressive neurosensory hearing loss-hypertrophic cardiomyopathy syndrome · progressive sensorineural deafness-hypertrophic cardiomyopathy syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1 matched papers (1 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 149 for broader category hypertrophic cardiomyopathy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1
1 paper have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 1 · MeSH hits: 0
Who's working on it?
2
Distinct author names in 1 sampled paper — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Guo S1 paper · 2024
Department of Vascular Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
Papers in Europe PMC - 02Zha L1 paper · 2024
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 149 trials are registered for hypertrophic cardiomyopathy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
149 interventional trials matched hypertrophic cardiomyopathy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: hypertrophic cardiomyopathy
149
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05818605·RECRUITING·Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Conditions: Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT06873828·NOT YET RECRUITING·Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Conditions: Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT05610215·RECRUITING·Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
Conditions: Atrial Fibrillation · Cardiomyopathy, Hypertrophic · Radiofrequency Ablation·Matched via name phrase
- NCT05836259·RECRUITING·Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Conditions: Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT05569382·RECRUITING·Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy
Conditions: Non-obstructive Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT07806149·NOT YET RECRUITING·NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Conditions: Hypertrophic Cardiomyopathy · Left Ventricular Outflow Obstruction · Systolic Anterior Motion·Matched via name phrase
- NCT06490250·RECRUITING·Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients
Conditions: Hypertrophic Cardiomyopathy · Heart Diseases·Matched via name phrase
- NCT06433050·RECRUITING·Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
Conditions: Hypertrophic Cardiomyopathy Without Obstruction·Matched via name phrase
- NCT07372196·RECRUITING·Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy
Conditions: HCM - Hypertrophic Cardiomyopathy · Sudden Cardiac Death · Left Bundle Branch Pacing · ICD·Matched via name phrase
- NCT06794710·NOT YET RECRUITING·Early Identification and Treatment of Rare Cardiomyopathy Cohorts
Conditions: Hypertrophic Cardiomyopathy (HCM) · Dilated Cardiomyopathy (DCM) · Metabolic Cardiomyopathy · Restrictive Cardiomyopathy·Matched via name phrase
- NCT06935253·RECRUITING·Large Language Models To Improve the Quality of Care of Cardiology Patients
Conditions: Hypertrophic Cardiomyopathy (HCM) · Cardiomyopathy · Genetic Disease · Cardiology·Matched via name phrase
- NCT07294495·NOT YET RECRUITING·Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
Conditions: HCM - Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT07202897·RECRUITING·LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Conditions: Hypertrophic Cardiomyopathy (HCM)·Matched via name phrase
- NCT07023614·RECRUITING·A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Conditions: Non-obstructive Hypertrophic Cardiomyopathy·Matched via name phrase
- NCT07595354·RECRUITING·Exercise Prescription in Children With Hypertrophic Cardiomyopathy
Conditions: Hypertrophic Cardiomyopathy Without Obstruction·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome" OR "Progressive neurosensory deafness-hypertrophic cardiomyopathy syndrome" OR "Progressive neurosensory hearing loss-hypertrophic cardiomyopathy syndrome" OR "Progressive sensorineural deafness-hypertrophic cardiomyopathy syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome" OR "Progressive neurosensory deafness-hypertrophic cardiomyopathy syndrome" OR "Progressive neurosensory hearing loss-hypertrophic cardiomyopathy syndrome" OR "Progressive sensorineural deafness-hypertrophic cardiomyopathy syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"hypertrophic cardiomyopathy"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:01:29.382Z
